Review and management of drug interactions with boceprevir and telaprevir

Hepatology

Volumn 55, Issue 5, 2012, Pages 1620-1628

  Kiser, Jennifer J ^a   Burton, James R ^a   Anderson, Peter L ^a   Everson, Gregory T ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ANTIRETROVIRUS AGENT; BOCEPREVIR; BUPRENORPHINE; CYCLOSPORIN; CYTOCHROME P450 3A; ESCITALOPRAM; ETHINYLESTRADIOL; GLYCOPROTEIN P; LUTEINIZING HORMONE; METHADONE; MEVINOLIN; MIDAZOLAM; NEUROLEPTIC AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROGESTERONE; RAPAMYCIN; RIBAVIRIN; RITONAVIR; SIMVASTATIN; TACROLIMUS; TELAPREVIR; ZOLPIDEM;

ALOPECIA; ANEMIA; ANTIVIRAL ACTIVITY; ANUS PRURITUS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; CHILL; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRY SKIN; DYSGEUSIA; DYSPNEA; FATIGUE; HEMORRHOID; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; IC 50; INSOMNIA; IRRITABILITY; LUTEINIZING HORMONE BLOOD LEVEL; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PRURITUS; REVIEW; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VIRUS LOAD; VOMITING;

ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OLIGOPEPTIDES; PROLINE; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84859955001     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25653     Document Type: Review

References (66)

1. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
2. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
4. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
5. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
6. Merck. Victrelis (boceprevir) prescribing information. May 2011. Available at: Accessed December 16, 2011.
7. CDER. Boceprevir: clinical pharmacology and biopharmaceutics review. April 20, 2011. Available at: Accessed December 14, 2011.
8. Silva M, Kasserra C, Gupta S, Treitel M, Hughes E, O'Mara E. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. In: 21st Conference of the Asian Pacific Association for the Study of the Liver. Bangkok, Thailand, February 17-20, 2011.
9. Vertex. Incivek (telaprevir) prescribing information. May 2011. Available at: Accessed December 16, 2011.
10. Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011; 140: 459-468 e451; quiz, e414.
11. van Heeswijk R, Boogaerts G, De Paepe E, Vangeneugden T, De Backer K, Beumont M, Garg V. The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir [abstract 19]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
12. HolisticOnline. Fat content of foods. Available at: Accessed December 2, 2011.
13. Chakilam A, Chavan A, Smith G, Lachau-Durand S, Garg V. Telaprevir binding to isolated human plasma proteins and protein binding displacement interactions between telaprevir and warfarin [abstract 20]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
14. Adiwijaya B, Chandorkar G, van Heeswijk R, McNair L, Kwo PY, Gordon S, Garg V. Effect of mild and moderate hepatic impairment on telaprevir pharmacokinetics [abstract 1]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
15. Peng J, Bertz R, Hsu A, Li J, Ashbrenner E, Grebner K, et al. Evaluation of single and multi dose pharmacokinetics of ritonavir in subjects with mild or moderate hepatic insufficiency [abstract 16: P 3.7]. In: 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, March 27-29, 2003.
16. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777.
17. CDER. Telaprevir: clinical pharmacology biopharmaceutics review. May 13 2011. Available at: Accessed December 14, 2011.
18. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002; 162: 405-412.
19. Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir [abstract 13]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
20. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
21. Garg V, Chandorkar G, Smith F, Alves K, van Heeswijk R. The effect of telaprevir on the pharmacokinetics of midazolam and digoxin [abstract 12]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
22. Garg V, van Heeswijk R, Eun Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. HEPATOLOGY 2011; 54: 20-27.
23. Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, et al. Pharmacokinetic Interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tacrolimus [abstract 123]. In: 16th Annual Meeting of HepDART, Koloa, Hawaii, December 4-8, 2011.
24. Teicher E, Vincent I, Bonhomme-Faivre L, Abbara C, Barrail A, Boissonnas A, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46: 941-952.
25. Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl 2004; 10: 939-944.
26. Frassetto LA, Browne M, Cheng A, Wolfe AR, Roland ME, Stock PG, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7: 2816-2820.
27. Guaraldi G, Cocchi S, Codeluppi M, Di Benedetto F, Bonora S, Motta A, et al. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006; 38: 1138-1140.
28. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353-367.
29. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8: 12-22.
30. DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 10, 2011. Available at: Accessed August 11, 2011.
31. Van Heeswijk R, Vandevoorde A, Boogaerts G, Vangeneugden T, De Paepe E, Polo R, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor telaprevir in healthy volunteers [abstract 119]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
32. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
33. BristolMyersSquibb. Reyataz (atazanavir) prescribing information. February 2011. Available at: Accessed August 12, 2011.
34. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278-283.
35. Hoetelmans RM, Marien K, De Pauw M, Hill A, Peeters M, Sekar V, et al. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers. Br J Clin Pharmacol 2007; 64: 655-661.
36. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197: 102-108.
37. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496-505.
38. Sherman KE, Rockstroh JK, Dieterich DT, Soriano V, Girard P-M, McCallister S, et al. Telaprevir in combination with peginterferon alfa 2a/ribavirin in HCV/HIV coinfected patients: a 24-week Treatment interim analysis [abstract LB-8]. In: 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, November 6-9, 2011.
39. Garg V, Luo X, McNair L, Van Heeswijk R, Kauffman RS. The effect of low-dose ritonavir on the pharmacokinetics of the investigational hepatitis C protease inhibitor telaprevir in healthy volunteers [abstract 629]. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, Feburary 27-March 2, 2011.
40. Sulkowski MS, Pol S, Cooper C, Fainboim H, Slim J, Rivero A, et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients [abstract LB-37]. In: Infectious Diseases Society of America 49th Annual Meeting, Boston, MA, October 20-23, 2011.
41. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-370.
42. Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-4574.
43. Hulskotte EGJ, Gupta S, Xuan F, Van Zutven MGJA, O'Mara E, Galitz L, et al. Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor boceprevir and the HMG-CoA reductase inhibitors atorvastatin and pravastatin [abstract 122]. In: 16th Annual HepDART, Koloa, Hawaii, December 4-8, 2011.
44. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47: 570-578.
45. Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2011 Jun 28. DOI: 10.1177/0091270011407494.
46. Busti AJ, Bain AM, Hall RG, 2nd, Bedimo RG, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008; 51: 605-610.
47. Genetech. Copegus (ribavirin) prescribing information. December 2010. Available at: Accessed August 15, 2011.
48. Garg V, Van Heeswijk R, Yang Y, Kauffman RS, Smith F, Adda N. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir. J Clin Pharmacol (Accepted).
49. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2010: CD007541.
50. Teter CJ, Kando JC, Wells BG. Major depressive disorder. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 8th ed. New York: McGraw Hill Medical; 2011: 1178.
51. Hulskotte EGJ, Gupta S, Xuan F, Van Zutven MGJA, O'Mara E, Galitz L, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers [abstract 121]. In: 16th Annual Meeting of HepDART, Koloa, Hawaii, December 4-8, 2011.
52. Van Heeswijk R, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12]. In: 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Boston, MA, June 23-24, 2010.
53. Best BM, Letendre S, Rossi S, Clifford D, Collier A, Gelman B, et al. Low exposure to paroxetine and sertraline, but not to citalopram, escitalopram, and fluoxetine in HIV-infected patients [abstract 574]. In: 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007.
54. Sekar V, De Paepe E, De Marez T, De Pauw M, Vangeneugden T, Lefebvre E, Hoetelmans RM. Pharmacokinetic interaction between darunavir (TMC114), a new protease inhibitor, and the selective serotonin reuptake inhibitors (SSRIs), paroxetine, and sertraline [abstract P295]. In: 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 12-16, 2006.
55. AstraZeneca. Seroquel (quetiapine). November 9, 2011. Available at: Accessed December 6, 2011.
56. Tseng A, Foisy M. Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012; 14: 67-82.
57. BristolMyersSquibb. Abilify (aripirazole) prescribing information. 2011. Available at: Accessed December 16, 2011.
58. Aung GL, O'Brien JG, Tien PG, Kawamoto LS. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother 2010; 44: 1850-1854.
59. Novartis. Fanapt (iloperidone) prescribing information. 2011. Available at: Accessed December 16, 2011.
60. Luo X, van Heeswijk R, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract 11]. In: 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011.
61. Greenblatt DJ, von Moltke LL, Harmatz JS, Fogelman SM, Chen G, Graf JA, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43: 414-422.
62. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16: 36-44.
63. Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984; 12: 577-581.
64. Van Heeswijk R, Vandevoorde A, Verboven P, Boogaerts G, De Paepe E, Van Solingen-Ristea R, et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir [abstract 654]. In: 46th Annual Meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
65. Luo X, Trevejo J, Van Heeswijk R, Garg V. No significant effect of the HCV protease inhibitor telaprevir on the pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers. In: 16th Annual Meeting of HepDART, Koloa, Hawaii, December 4-8, 2011.
66. Christian H, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists, and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol 2010; 6: 199-211.